Coherus Biosciences Inc. (CHRS)
NASDAQ · Healthcare
Coherus Biosciences Inc. Total Liabilities 2012–2025
Coherus Biosciences Inc. annual total liabilities history from 2013 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Coherus Biosciences Inc. total liabilities as of December 31, 2025: 197.3M, a 66.01% decrease year-over-year.
- Coherus Biosciences Inc. total liabilities for 2025 were 197.3M, a 66.01% decrease from 2024.
- Coherus Biosciences Inc. total liabilities for 2024 were 580.5M, a 29.47% decrease from 2023.
- Coherus Biosciences Inc. total liabilities for 2023 were 823.0M, a 33.12% increase from 2022.
- Coherus Biosciences Inc. total liabilities for 2022 were 618.3M.
Total Liabilities
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Coherus Biosciences Inc. Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $197 |
| 2024 | $581 |
| 2023 | $823 |
| 2022 | $618 |
| 2021 | $582 |
| 2020 | $561 |
| 2019 | $304 |
| 2018 | $138 |
| 2017 | $132 |
| 2016 | $159 |
| 2015 | $219 |
| 2014 | $120 |
| 2013 | $90 |
Coherus Biosciences Inc. Total Liabilities — FAQ
Coherus Biosciences Inc. (CHRS) total liabilities over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CHRS's total liabilities history?
The chart and table above show Coherus Biosciences Inc.'s total liabilities by year and by quarter, including the growth rate.